Last reviewed · How we verify
IFN-alpha
Interferes with viral replication by binding to the cell surface receptor for the virus.
Interferes with viral replication by binding to the cell surface receptor for the virus. Used for Hairy cell leukemia, Chronic myelogenous leukemia, Multiple sclerosis.
At a glance
| Generic name | IFN-alpha |
|---|---|
| Also known as | Referon-A |
| Sponsor | Active Biotech AB |
| Drug class | Interferon |
| Target | IFN-alpha receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This binding prevents the virus from entering the host cell, thereby inhibiting viral replication.
Approved indications
- Hairy cell leukemia
- Chronic myelogenous leukemia
- Multiple sclerosis
Common side effects
- Flu-like symptoms
- Fatigue
- Headache
Key clinical trials
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (PHASE3)
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (PHASE3)
- Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer (PHASE1, PHASE2)
- Effectiveness of Zidovudine vs. Zidovudine Plus Alpha Interferon vs. Interferon for Treatment of HIV
- High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma (PHASE3)
- Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (PHASE2)
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IFN-alpha CI brief — competitive landscape report
- IFN-alpha updates RSS · CI watch RSS
- Active Biotech AB portfolio CI